Pharma BD Deal Intelligence

Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc.

2012 · Acquisition/Merger · $230M · Complete

Announcement Sentiment

Strongly positive

Sun Pharma tender offer at $8/share cash for DUSA (~$230M; 38% premium). Acquired Levulan photodynamic therapy platform for AK and acne, providing Sun's first US dermatology branded entry.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Nov 08, 2012
Closed Dec 31, 2012
Deal value $230M
Deal type Acquisition/Merger
Therapeutic area Actinic keratoses (face/scalp); inflammatory acne
Indications Actinic keratoses (face/scalp); inflammatory acne
Key assets Levulan Kerastick (aminolevulinic acid HCl) + BLU-U photodynamic therapy device
Mechanism Photodynamic therapy (porphyrin precursor)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals